CellBion Co., Ltd. (KOSDAQ:308430)

South Korea flag South Korea · Delayed Price · Currency is KRW
18,630
-100 (-0.53%)
At close: Sep 19, 2025
-0.53%
Market Cap238.81B
Revenue (ttm)2.63B
Net Income (ttm)-7.43B
Shares Out12.82M
EPS (ttm)-665.27
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume136,848
Average Volume409,874
Open18,750
Previous Close18,730
Day's Range18,580 - 19,020
52-Week Range9,930 - 29,600
Betan/a
RSI29.92
Earnings DateNov 13, 2025

About CellBion

CellBion Co., Ltd. engages in the research and development of radiopharmaceutical products. Its clinical stage pipeline includes 177Lu-PSMA-DGUL, indicated for prostate cancer radiotherapy, currently under Phase 2 clinical stage; 225Ac-Antibody, indicated for multiple cancer types, currently under pre-clinical stage; 225Ac-DGUL, indicated for prostate cancer radiotherapy, currently under pre-clinical stage; 68Ga-Nota-MSA, indicated for cardiovascular disease diagnosis, currently under Phase 2 clinical stage; 99mTc-MSA-ICG, indicated for lymphos... [Read more]

Industry Pharmaceutical Preparations
Founded 2010
Employees 57
Stock Exchange KOSDAQ
Ticker Symbol 308430
Full Company Profile

Financial Performance

In 2024, CellBion's revenue was 2.29 billion, an increase of 55.64% compared to the previous year's 1.47 billion. Losses were -7.27 billion, 100.0% more than in 2023.

Financial Statements

News

There is no news available yet.